BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9196154)

  • 21. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
    Hainsworth JD; Daugaard G; Lesimple T; Hübner G; Greco FA; Stahl MJ; Büschenfelde CM; Allouache D; Penel N; Knoblauch P; Fizazi KS
    Cancer; 2015 May; 121(10):1654-61. PubMed ID: 25611313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
    Greco FA; Johnson DH; Hainsworth JD
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary.
    El-Rayes BF; Shields AF; Zalupski M; Heilbrun LK; Jain V; Terry D; Ferris AM; Philip PA
    Am J Clin Oncol; 2005 Apr; 28(2):152-6. PubMed ID: 15803009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study.
    Briasoulis E; Tsavaris N; Fountzilas G; Athanasiadis A; Kosmidis P; Bafaloukos D; Skarlos D; Samantas E; Pavlidis N
    Oncology; 1998; 55(5):426-30. PubMed ID: 9732220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).
    Warner E; Goel R; Chang J; Chow W; Verma S; Dancey J; Franssen E; Dulude H; Girouard M; Correia J; Gallant G
    Br J Cancer; 1998 Jun; 77(12):2376-80. PubMed ID: 9649162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Johnson DH; Greco FA
    Semin Oncol; 1992 Apr; 19(2 Suppl 5):54-7; discussion 58. PubMed ID: 1384145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
    Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
    Hainsworth JD; Johnson DH; Greco FA
    J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report.
    Bonomi P; Faber LP; Recine D; Lincoln S
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):42-7. PubMed ID: 7644927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
    Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.
    Mikhail S; Lustberg MB; Ruppert AS; Mortazavi A; Monk P; Kleiber B; Villalona-Calero M; Bekaii-Saab T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1005-12. PubMed ID: 26416564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Rose PG; Rodriguez M; Waggoner S; Greer BE; Horowitz IR; Fowler JM; McGuire WP
    J Clin Oncol; 2000 Aug; 18(16):2957-62. PubMed ID: 10944128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.
    Motzer RJ; Mazumdar M; Sheinfeld J; Bajorin DF; Macapinlac HA; Bains M; Reich L; Flombaum C; Mariani T; Tong WP; Bosl GJ
    J Clin Oncol; 2000 Mar; 18(6):1173-80. PubMed ID: 10715285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evolving role of paclitaxel for patients with carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):129-33. PubMed ID: 10190795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
    Miller AA; Wang XF; Bogart JA; Hodgson LD; Rocha Lima CM; Radford JE; Vokes EE; Green MR;
    J Thorac Oncol; 2007 Jul; 2(7):645-51. PubMed ID: 17607121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule.
    Groen HJ; Fokkema E; Biesma B; Kwa B; van Putten JW; Postmus PE; Smit EF
    J Clin Oncol; 1999 Mar; 17(3):927-32. PubMed ID: 10071286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.